A new vaccine designed to prevent smokers from absorbing nicotine from cigarettes, called NicVax, is currently undergoing trials in the United States.
 |
(Image: centumcellae.it) |
The vaccine reduces the pleasure derived from smoking by producing antibodies that bind to nicotine molecules, preventing them from entering the brain. Each injection lasts approximately one month.
Currently, 300 individuals are receiving repeated doses to determine if the effects last for several months and assist in quitting smoking. If the trials prove successful, NicVax could be released to the market within three years.
Dr. Victor Reus, who is leading the research and is a professor of psychiatry at the University of California, mentioned that the main issue is whether the booster shots will help individuals overcome their addiction to smoking.
Meanwhile, Thomas Rathjen, a spokesperson for Nabi Biopharmaceuticals, the company developing NicVax, stated that the research results will be published next year.
K.NHẬT
